Lead Product(s) : Cyclosporine,Benzalkonium Chloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Entod Pharmaceuticals Launches CYCLOTEARS Eye Drops
Details : Cyclotears 0.05% eye drops contains cyclosporin which belongs to the group of medicines called Immunosuppressants. It is used to treat severe dry eye syndrome (keratoconjunctivitis sicca) in children and in adolescents (aged between 4-18 years).
Product Name : Cyclotears
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 04, 2023
Lead Product(s) : Cyclosporine,Benzalkonium Chloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : ITEC Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Benzalkonium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Contraception.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2017
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : ITEC Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacodynamic and Safety Study of BCS in Healthy Volunteers
Details : Benzalkonium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2015
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD
Details : Benzalkonium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2014
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Patch Test of Benzalkonium Chloride Disinfectant Spray
Details : Benzalkonium Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Wound Healing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2013
Lead Product(s) : Benzalkonium Chloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
